Taysha Gene Therapies (NASDAQ:TSHA) filed a prospectus for a mixed shelf offering of up to $300 million. The preliminary prospectus is not an offer to sell. Filing Taysha Gene Therapies ...

Taysha Gene Therapies (TSHA) announced that, on March 3, 2025, the Compensation Committee of Taysha’s Board of Directors granted three new employees, in the aggregate, options to purchase ...

Taysha Gene Therapies Stock Down 1.7 % Shares of NASDAQ:TSHA opened at $1.72 on Tuesday. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. The ...

DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies ...

The stock options have an exercise price of $1.62 which is equal to the closing price of Taysha's common stock on the date of grant. The stock option has a 10-year term and will vest over four ...